Next-generation psychedelic and cannabinoid medicines
Discovery
Preclinical
Phase 1
Phase 2
EV101:GBM
Glioblastoma Multiforme
EV102:RD
Radiation Dermatitis
EVM201:CRD
Cancer Related Distress
EVM202:PTSD
Post-traumatic Stress Disorder
Glioblastoma Multiforme (GBM)
CBD has the potential to influence many of the key pathways involved in Glioblastoma pathogenesis, from tumor stemness and proliferation to angiogenesis and local invasion. Glioblastoma tumors express CB2 receptors, through which CBD and other cannabinoids are thought to exert their anti-cancer efforts (Ellert-Miklaszewska, Adv Exp Med Biol, 2013). Developing clinical trials to evaluate CBD combination therapies’ efficacy may represent an important next step toward improving the standard of care for treating glioblastoma for a population of patients with few effective therapeutic options available.
Radiation Dermatitis
Radiodermatitis (also called radiation dermatitis) is a skin condition caused by the high-energy X-rays delivered during radiation therapy. It affects nearly 95% of patients who receive radiation for cancer treatment, with approximately 85% of patients having moderate-to-severe skin reactions.
Clinicians generally believe that the ideal method for preventing and minimizing skin reactions to radiation treatment is to provide anti-inflammatory and anti-microbial solutions at the cellular level and moisturization of the irradiated area. The current standard of care involves using a simple topical product with petrolatum to provide moisturization and occlusivity to the irradiated area, yet this has left both patients and doctors searching for more effective medicine.
CBD therapy works by interacting with the body’s Endocannabinoid System, which plays an essential role in regulating skin health. When CBD and other cannabinoids interact with the skin receptors, they appear to play a role in controlling inflammation levels and bolster immune response.


”With both psychedelic derived molecules and cannabinoids, we have a robust pipeline to take us from discovery through clinical development. Our platform has the potential to disrupt and unlock much needed mental health treatments through psychedelic therapies. We have brought together pharma and biotech experts with years of experience in bringing innovative treatments to market as well as a discovery team with a world-class biotech laboratory. We are dedicated to our mission to advance the next generation of treatments.
Dr. Joseph TuckerCEO of Enveric
Discovering Next-generation Treatments for the Mind and Body
Our mission is to improve the characteristics of psychedelic- and cannabinoid-derived pharmaceuticals by unlocking their full potential to create treatment solutions for a growing and underserved patient population.
